We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Two scientists performing chemical analysis

Fourth quarter and full year results 2022 and Annual Report 2022 publication

Walkway at the entrance of the Novartis Campus in Basel, Switzerland

Investors Event Calendar

View recent presentations and learn more about upcoming events.

Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy

Novartis Annual Reporting Suite

Read and download our integrated report, annual regulatory filings, and other disclosures.

Doctor prescribing medication in Rwanda

Environmental, Social and Governance (ESG)

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

ESG Updates: Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB)
Latest updates: Investor Update on Access & Sustainability (PDF 1.6 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB)  | Materiality Assessment

We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.



Pulse Updates

January 09, 2023

Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023

Read more

December 16, 2021

Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

Read more


September 28, 2021

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Read more

September 03, 2021

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

Read more

Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.


Stay Up-to-Date

Stay connected to the latest news and information from Novartis.


Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland